Elesclomol, an experimental anticancer drug, could have potential to also treat copper-deficiency diseases, including Menkes disease. Although this copper-transporting compound has been shown to relieve copper deficiency in a variety of animal models, the mechanism by which it delivers copper to where it is needed inside cells has remained unknown.